Acceleron Pharma Inc Patent Filing for Spinal Muscular Atrophy Treatment

According to GlobalData’s company profile on Acceleron Pharma, was a key innovation area identified from patents.

Treatment of spinal muscular atrophy using alk4:actriib antagonists

A recently granted patent (Publication Number: US11857599B2) outlines a method for treating spinal muscular atrophy (SMA) in patients by administering a recombinant ALK4:ActRIIB heteromultimer. This treatment involves the use of ALK4-Fc fusion protein and ActRIIB-Fc fusion protein, each containing specific amino acid sequences and Fc domain polypeptides. The method aims to prevent or reduce the severity of complications associated with SMA, such as muscle weakness, respiratory issues, bone loss, and developmental delays.

Furthermore, the patent details various aspects of the treatment method, including its application in patients with SMA3, its potential to increase bone mineral density and muscle mass, and its ability to improve motor function and milestones. The method also allows for the administration of additional active agents or supportive therapies alongside the recombinant heteromultimer, such as nusinersen or other treatments targeting SMA. The patent emphasizes the importance of specific amino acid sequences and fusion protein compositions in achieving the desired therapeutic effects, highlighting the precision and specificity of the proposed treatment approach for SMA patients.

To know more about GlobalData’s detailed insights on Acceleron Pharma, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies